Tourmaline Bio, Inc. — Director's Dealing 2021

May 7, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Talaris Therapeutics, Inc. (TALS)
CIK: 0001827506
Period of Report: 2021-05-06

Reporting Person: Nader Francois (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	395687	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$5.72	2030-10-02	Common Stock (81373)		Direct

Footnotes

F1: These shares vest in 48 equal monthly installments beginning on October 2, 2020.